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ABSTRACT
Background
Plasmodium vivax invasion requires interaction between the human Duffy antigen on the
surface of erythrocytes and the P. vivax Duffy binding protein (PvDBP) expressed by the
parasite. Given that Duffy-negative individuals are resistant and that Duffy-negative
heterozygotes show reduced susceptibility to blood-stage infection, we hypothesized that
antibodies directed against region two of P. vivax Duffy binding protein (PvDBPII) would inhibit
P. vivax invasion of human erythrocytes.
Methods and Findings
Using a recombinant region two of the P. vivax Duffy binding protein (rPvDBPII), polyclonal
antibodies were generated from immunized rabbits and affinity purified from the pooled sera
of 14 P. vivax–exposed Papua New Guineans. It was determined by ELISA and by flow
cytometry, respectively, that both rabbit and human antibodies inhibited binding of rPvDBPII
to the Duffy antigen N-terminal region and to Duffy-positive human erythrocytes. Additionally,
using immunofluorescent microscopy, the antibodies were shown to attach to native PvDBP on
the apical end of the P. vivax merozoite. In vitro invasion assays, using blood isolates from
individuals in the Mae Sot district of Thailand, showed that addition of rabbit anti-PvDBPII Ab or
serum (antibodies against, or serum containing antibodies against, region two of the
Plasmodium vivax Duffy binding protein) (1:100) reduced the number of parasite invasions by
up to 64%, while pooled PvDBPII antisera from P. vivax–exposed people reduced P. vivax
invasion by up to 54%.
Conclusions
These results show, for what we believe to be the first time, that both rabbit and human
antibodies directed against PvDBPII reduce invasion efficiency of wild P. vivax isolated from
infected patients, and suggest that a PvDBP-based vaccine may reduce human blood-stage P.
vivax infection.
The Editors’ Summary of this article follows the references.
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Plasmodium vivax accounts for at least half of all malaria
cases in Latin America, Oceania, and Asia [1]; 70 to 80 million
clinical P. vivax cases occur worldwide annually. While
Plasmodium falciparum uses a complex array of receptors to
invade human erythrocytes [2–6], erythrocyte invasion by P.
vivax, and the closely related simian parasite Plasmodium
knowlesi, are understood to depend upon interaction with the
Duffy blood group antigen [7,8]. In the homologous P. knowlesi
system, merozoites interact with Duffy-negative human red
blood cells, but are unable to invade [8,9]. In Africa, where
Duffy-negativity has reached ﬁxation in many different
ethnicities, transmission of P. vivax malaria is uncommon
[1,10]. Of further interest, in Papua New Guinea, hetero-
zygous carriers of a Duffy-negative allele are shown to express
half the amount of the Duffy antigen on erythrocytes
compared to wild-type homozygotes [11], and exhibit reduced
susceptibility to P. vivax blood-stage infection [12]. These
observations suggest that completely or partially disrupting
access to the Duffy antigen reduces the ability of the parasite
to invade new erythrocytes and may constrain P. vivax
parasitemia.
The Duffy antigen shares structural features with chemo-
kine receptors (which have the alternative name of Duffy
antigens/receptors for chemokines [DARC]) [13], and exhibits
binding to a unique array of chemokines [14–16]; however,
because the Duffy protein has no known signaling function, it
is no longer included in the chemokine receptor nomencla-
ture system [17]. The Duffy binding protein (DBP), a 140-kD
transmembrane protein, serves as the parasite ligand in P.
vivax and P. knowlesi erythrocyte-invasion complexes [18–21].
The protein is characterized by two cysteine-rich regions (II
and IV) sharing amino acid sequence homology with other
malaria parasite erythrocyte-binding ligands [2]. To date, P.
vivax DBPII and orthologous P. knowlesi DBPa (71% sequence
identity) are the only parasite ligands known to bind Duffy
[20,21]. A number of competitive binding [16,22] and gene-
deletion [23] strategies have demonstrated the importance of
the DBP–Duffy interaction in regard to a range of parasite–
host processes leading to erythrocyte invasion. Of greatest
relevance to our current study, antibodies generated against
P. knowlesi DBPa inhibit P. knowlesi invasion of both human
and rhesus erythrocytes in vitro [24]. At present, it is not
known whether antibodies against region two of the P. vivax
Duffy binding protein (PvDBPII) can also inhibit erythrocyte
invasion of P. vivax.
Recent advances have made it possible to express refolded
recombinant region two of the P. vivax Duffy binding protein
(rPvDBPII), which exhibits the Duffy antigen-binding char-
acteristics of the full-length parasite protein [25]. With this
puriﬁed protein, it has become possible to develop PvDBPII-
speciﬁc antibodies for further studies evaluating P. vivax
Duffy binding protein (PvDBP) [26]. Additionally, recent
progress in culturing P. vivax ﬁeld isolates in vitro [27,28]
presents new opportunities to improve understanding of the
mechanisms of P. vivax invasion and the ability of antibodies
directed against merozoite antigens to inhibit parasite
invasion and/or growth in erythrocytes. More speciﬁcally,
we aim to determine whether molecular inhibition of
PvDBP–Duffy binding translates into inhibition of P. vivax
invasion of human erythrocytes. Here, we conducted a series
of in vitro studies to purify rabbit and human PvDBPII-
speciﬁc polyclonal antibodies that inhibit PvDBP–Duffy
binding. We then used these reagents to test the hypothesis
that human PvDBPII-speciﬁc antibodies are able to inhibit in
vitro invasion of human erythrocytes by P. vivax.
Materials and Methods
Human Blood Samples
All human blood samples used in this study were collected
after obtaining consent from study participants under
protocols approved by the Ethical Review Board of the
Cleveland Veteran’s Administration Medical Center, the
Papua New Guinea Medical Research Advisory Committee,
the Ethical Review Committee of Mahidol University, the
Thai Ministry of Public Health, and the United States Army.
For short-term culture studies, blood infected with P. vivax
was collected from adult males from an endemic area along
the Thailand/Myanmar border who presented with clinical
malaria at the Mae Sot clinic. P. vivax infection was conﬁrmed
by thick- and thin-smear blood ﬁlms using standard Giemsa
staining techniques and light microscopy [29,30]. Coinfection
by other malaria species was ruled out by light microscopy
and OptiMAL antigen-capture stick tests [31]. Plasma samples
for isolating human anti-PvDBPII Ab (antibodies against
region two of the Plasmodium vivax Duffy binding protein)
were obtained from P. vivax–exposed patients (aged 12–43 y)
from the Wosera region of the East Sepik province, a malaria-
holoendemic area of Papua New Guinea [32]. All blood was
collected in heparin or EDTA vacutainers and used as whole
blood for parasite culture or as plasma to isolate human anti-
PvDBPII Ab (cryopreserved at  80 8C).
Expression, Refolding, and Purification of Recombinant
PvDBPII
Production and puriﬁcation of recombinant P. vivax DBPII
variants (Salvador 1 [Sal 1] and C [33]) followed methods
described previously by Singh et al. [25]. Details of the
experimental approach used and the results obtained are
elaborated in Figure S1. Recombinant PvMSP119 (Plasmodium
vivax merozoite surface protein-1 19) was kindly provided by
T. Stowers of the Malaria Vaccine Unit, National Institute of
Allergy and Infectious Diseases, at the US National Institutes
of Health.
Preparation of Anti-PvDBPII Ab
Recombinant PvDBPII (100 lg) was injected into rabbits
intramuscularly at 3-wk intervals, emulsiﬁed in Titermax
Gold (CytRx). The IgG fraction of the serum was puriﬁed
using a protein-G column. Cryopreserved plasma samples
from adults residing in P. vivax–endemic areas of Papua New
Guinea were initially screened for the presence of anti-
PvDBPII Ab (below). Plasma samples were pooled from P.
vivax–exposed individuals (n ¼ 14; with ELISA optical density
values ﬁve times greater than in unexposed individuals), and
from P. vivax–unexposed individuals (n ¼ 7). Human anti-
PvDBPII Ab was afﬁnity puriﬁed by passing the clariﬁed
pooled human plasma over an afﬁnity column made by
binding 5 mg of the rPvDBPII protein to cyanogen bromide–
activated sepharose beads. The column was washed with three
volumes of PBS, pH 7.4, and bound antibodies were released
from the column using an elution buffer (0.1 M glycine-HCl,
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neutralized by adding 0.1 volumes of 1 M Tris-HCl (pH 8.5)
and then dialyzed against PBS. The amount of total IgG in the
eluate and its ability to bind to the rPvDBPII were
determined by ELISA.
ELISA-Based Binding-Inhibition Assay
A construct encoding the N-terminal 60 codons of the
human DARC protein was ligated to the sequence encoding
the Fc region of human IgG (nDARC-Ig) and cloned into the
mammalian expression vector pCDM8 [34–36]. As Choe et al.
have demonstrated that sulfonation of tyrosine at amino acid
41 of the human Duffy antigen is essential for interaction
with rPvDBPII, nDARC-Ig was expressed following cotrans-
fection of mammalian cells with plasmids encoding nDARC-
Ig and human tyrosyl protein sulfotransferase-2 [34]. The
expressed recombinant protein was puriﬁed from cell culture
supernatants by afﬁnity chromatography using Protein A
(Pierce). The nDARC-Ig chimeras were further puriﬁed by gel
ﬁltration chromatography using Superdex 200 (Amersham
Biosciences) in PBS together with 300 mM NaCl. Recombi-
nant nDARC-Ig (1 lg/ml) in 50 ll of NaHCO3 (pH 9.6) was
added to Immulon 4 ELISA plates and incubated overnight at
4 8C. Recombinant PvDBPII protein (0.1 lg/ml) was added to
allow binding to nDARC-Ig for 2 h at 37 8C. Bound rPvDBPII
was detected with rabbit anti-PvDBPII serum (serum con-
taining antibodies against region two of the Plasmodium vivax
Duffy binding protein) (1:8,000 dilution) followed by an
alkaline phosphatase–conjugated goat anti-rabbit antibody
(1:5,000 dilution; Jackson ImmunoResearch). Binding-inhib-
ition experiments were performed by pre-incubating
rPvDBPII (0.1 lg/ml) with rabbit or human antibodies for 1
ha t3 78C before adding to the nDARC-Ig–coated plate. The
mAb Fy6 (50 lg/ml), recognizing N-terminal amino acids 19–
25 of the Duffy antigen [37,38] inhibited binding of rPvDBPII
to human erythrocytes as expected at levels comparable to
those observed for the anti-PvDBPII Ab (unpublished data).
All parallel experiments were run with Duffy-negative cells
and detectable binding was always ,5% (unpublished data).
Fy6 [39] was obtained from BD Biosciences Pharmingen.
Erythrocyte-Binding Assays
Assays were performed by incubating donor erythrocytes
(10
6) with rPvDBPII (1 lg) for 4 h at room temperature or
overnight at 4 8C in 100 ll of PBS together with 1% BSA. Each
sample was washed three times with PBS and 1% BSA and
incubated (1 h in the dark at 4 8C) with mouse anti-HIS
antibody (1:25 dilution) conjugated to Alexa Fluor 488
(Qiagen). Samples were then washed four times with PBS
plus 1% BSA and resuspended in the same solution (200 ll).
LSRII-based (Becton-Dickinson) ﬂow cytometry evaluated
50,000 cells. To evaluate the ligand–receptor inhibitory
ability, rabbit and human anti-PvDBPII Ab were incubated
with rPvDBPII at the speciﬁed dilutions for 1 h at 37 8C
before combining with donor erythrocytes. Percent binding
was evaluated by assessing the percentage of erythrocytes
with bound rPvDBPII following exposure to test serum
divided by the percentage of erythrocytes with bound
rPvDBPII following exposure to pre-bleed serum (rabbit) or
equivalent concentrations of puriﬁed human IgG from non-
malaria exposed individuals and multiplied by 100.
Immunofluorescent Microscopy
Blood from patients infected with P. vivax or P. falciparum
parasites was added to a 60% Percoll column and centrifuged
at 1,000g for 10 min [28,40] to enrich collection of
erythrocytes infected with viable schizont-infected erythro-
cytes. For immunoﬂuorescent microscopy, thin-smear prep-
arations were made on glass slides and ﬁxed with cold
acetone for 10 min at  20 8C. After drying, slides were
blocked with reconstituted 5% w/v powdered milk for 10 min
at 37 8C in a moist dark environment. Slides were then
washed twice with PBS. The primary anti-PvDBPII Ab was
then applied and incubated for 15 min as described above.
After washing twice with PBS, goat anti-rabbit conjugated to
FITC (1:1,000) and Hoechst 33342 (0.01mg/ml; DNA stain)
were added. Slides were incubated for 30 min, then washed
three times in PBS and allowed to dry in the dark.
Fluorescent stains were ﬁxed onto the slides using Slow-Fade
anti-fade (Molecular Probes) and visualized using an Olympus
1003 oil-immersion lens.
P. vivax Invasion-Inhibition Assay
In vitro invasion assays were performed by ﬁrst collecting
;5 ml of whole peripheral venous blood (heparin vacutainer)
from two adult P. vivax–infected donors visiting the Malaria
Clinic in Mae Sot, Thailand. Donated blood was washed three
times in McCoy’s 5A medium (Sigma) supplemented with 25
mM HEPES, 0.25% NaHCO3, 2.2 mM L-glutamine, 0.08 mg/ml
gentamicin, and 25% human AB serum (PvCM and AB25).
After washing, the blood was depleted of leukocytes using a
CF 11 cellulose powder (Whattman) column [27], resus-
pended in PvCM plus AB25 at a 5% hematocrit, and
transported to the laboratory in Bangkok at ambient
temperature within 48 h. P. vivax–infected cultures (10 ml)
were grown at 37 8Ci n5 %C O 2,5 %O 2, and 90% N2 and
were maintained by replacing the PvCM plus AB25 daily until
predominately late-stage P. vivax–infected erythrocytes were
observed. At this point, the parasite cultures were divided
and added to individual wells of 96-well microtiter plates (200
ll), at 5% hematocrit, to evaluate invasion in the presence or
absence of antibodies. To maximize the amounts of anti-
bodies that were tested in Experiment 1, human AB serum in
the culture was lowered to 20% (PvCM and AB20). Rabbit
anti-PvDBPII serum, diluted 1:10, or human anti-PvDBPII Ab
diluted to concentrations of 37 and 150 lg/ml was added
upon initiation of the P. vivax cultures using the erythrocytes
from the ﬁrst patient. Experiment 2 utilized the standard
amount of human AB serum (25%), culturing the parasites in
PvCM plus AB25 with the erythrocytes from the second
patient and diluting rabbit anti-PvDBPII serum 1:100, or
1:1,000. Experiment 2 utilized human anti-PvDBPII Ab, which
was diluted to the ﬁnal concentrations of 25 and 100 lg/ml.
All cultures were grown at 5% hematocrit as described above
for 24 h. To assess the number of new P. vivax invasion events,
multiple thin smears were prepared from each culture
condition (triplicate wells), and then ﬁxed in 95% ethanol
before staining with 4% Giemsa (Sigma). To determine
parasitemia, a total of 200 high-powered microscope (1003
oil immersion) ﬁelds were counted with approximately 100
erythrocytes per ﬁeld for each condition (;20,000 red blood
cells). The microscopist was blinded to the experimental
conditions. All infected erythrocytes were counted and
classiﬁed from early ring forms through schizont and
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predominantly schizont developmental stages, any rings
through early trophozoites observed after culturing were
considered to be new invasions since these developmental
stages are known to occur within the 24-h time frame of the
short-term culture.
Statistical Analysis
Independent two-sided Student’s t-tests for equal variances
were performed using GraphPad Prism version 4.0 (Graph-
Pad Software) to assess differences in binding inhibition
between mean values of control and experimental treat-
ments. p-Values of less than 0.05 were considered signiﬁcant.
Results
Anti-PvDBPII Ab Inhibit Binding of rPvDBPII to Duffy
Antigen In Vitro
Our studies were initiated by expression of rPvDBPII
containing the minimal binding region for parasite binding
to the Duffy antigen. The antibodies speciﬁc for this protein
were characterized using serial dilutions to determine end-
point titers for both rabbit and human anti-bodies directed
to PvDBPII (Figure S2). Preferential enrichment for human
antibodies to rPvDBPII by afﬁnity puriﬁcation was conﬁrmed
by marked reduction in antibodies directed against PvMSP119
(Figure S2B) and failure of enriched antibodies to recognize
ﬁxed P. falciparum trophozoites and schizonts by immuno-
ﬂuorescence microscopy (unpublished data).
As interpretation of the protein–protein interactions
involved in ligand–receptor binding and further antibody-
based interference has the potential to be complex, we
analyzed PvDBPII–Duffy binding by three different in vitro
assays. As a ﬁrst approach, we evaluated rPvDBPII–Duffy
interaction in a cell-free system initially described by Choe et
al. [34]. Here, the rPvDBPII was allowed to interact with the
60 N-terminal amino acids of the Duffy antigen of the
chimeric protein, nDARC-Ig. The results presented in Figure
1A and 1B show that the rabbit polyclonal and afﬁnity-
puriﬁed human anti-PvDBPII Ab each inhibit rPvDBPII
binding to nDARC-Ig in a dose-dependent fashion similar
to that observed in previous binding assays. Levels of rabbit
and human antibodies corresponding to 50% inhibition of
binding were less than the 1:1,000 dilution rate and were
between 3 and 30 lg/ml, respectively.
As a second approach, we evaluated PvDBPII–Duffy bind-
ing and antibody interference by observing interaction
between PvDBPII on the surface of transfected COS7 cells
[41] and erythrocytes from Duffy-positive donors. Binding of
the erythrocytes to the COS7 cells was assessed by the
formation of rosettes. The disruption of the PvDBPII–Duffy
interaction was indicated by the absence of rosette formation.
Pre-incubation of COS7 PvDBPII transfectants with a 1:3,200
dilution of the rabbit anti-PvDBPII serum inhibited binding
to erythrocytes from Duffy-positive donors by 50% compared
to the pre-bleed serum (see Figure S3).
Finally, we use a ﬂow-cytometric approach to assess
binding of rPvDBPII to Duffy-positive erythrocytes and
binding inhibition by both rabbit and human anti-PvDBPII
Ab. For this assay, refolded rPvDBPII protein was incubated
with test serum prior to mixing with Duffy-positive or
-negative erythrocytes. Increasing the dilutions of rabbit
anti-PvDBPII serum inhibited binding to erythrocytes rela-
tive to pre-bleed rabbit serum in a dose-dependent fashion
(Figure 2A). Addition of varying concentrations of human
IgG enriched for anti-PvDBPII Ab also inhibited binding in a
dose-dependent fashion (Figure 2B). Similar to the nDARC-Ig
ELISA results described above, we observed that 50% binding
inhibition was observed for rabbit and human antibodies,
corresponding approximately to a 1:1,000 dilution and to a
range of 37–75 lg/ml, respectively.
Antibodies Recognize Native PvDBPII of P. vivax
Merozoites
We were interested to determine whether the afﬁnity-
puriﬁed anti-PvDBPII Ab reacted with native PvDBP of
merozoites. DBP is sequestered in the microneme apical
organelles until invasion is initiated [18]. Therefore, we
expected to see immunoﬂuorescence localization anterior to
the nucleus in mature merozoites of late-stage schizonts. To
evaluate anti-PvDBPII Ab recognition of native parasite
PvDBP, we applied rabbit anti-PvDBPII serum to thin-smear
preparations of schizont-enriched P. vivax samples. We also
incubated these same preparations with the DNA-speciﬁc
dye, Hoechst 33342, to identify nuclei of individual mer-
ozoites. The immunoﬂuorescence microscopy results pre-
sented in Figure 3 illustrate that the rabbit anti-PvDBPII
serum binds to the apical end of the P. vivax merozoite where
PvDBP expression would be expected to occur [18]. In this
same preparation, our immunoﬂuorescence results also show
anti-PvDBPII Ab recognition of developing merozoites within
a schizont-infected erythrocyte as well as the absence of
antibody recognition of structures within trophozoites.
Similar results were observed with the human anti-PvDBPII
Ab afﬁnity puriﬁed from P. vivax–exposed individuals from
Papua New Guinea (unpublished data).
Anti-PvDBPII Ab Decrease P. vivax Human Erythrocyte
Invasion
Finally, with results suggesting that the human and rabbit
anti-PvDBPII Ab–speciﬁc sera recognize native PvDBP and
Figure 1. Inhibition of nDARC-Ig Binding to rPvDBPII by Antibodies
Rabbit (A) and human (B) anti-PvDBPII Ab were tested to observe
inhibition of the interaction of the rPvDBPII protein and the N-terminal
region of Duffy in the nDARC-Ig chimera. In ELISA-based nDARC-Ig
assays, bars indicate the mean binding percentage relative to pre-bleed
rabbit serum or nonspecific human IgG (120 lg/ml). Duplicate experi-
ments showed variation of ,5%.
doi:10.1371/journal.pmed.0040337.g001
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antibodies inhibit P. vivax invasion of human red blood cells.
For these studies, we evaluated the progress of P. vivax
development from the late schizont stage for 24 h to
enumerate the appearance of ring and trophozoite stages
that would signal new red cell–invasion events. Table 1 shows
the results of two successful parasite invasion trials, in which
parasites were cultured in the absence of the anti-PvDBPII Ab
for 24 h. Over this time period, the percentage of schizont
and late-trophozoite developmental stages decreased as the
parasites matured and ruptured their host cells, while the
number of rings, early trophozoites, increased resulting in a
doubling in parasitemia—all of which suggest successful
invasion of new red blood cells. These results provided a
point of comparison for evaluating the inhibition by anti-
PvDBPII Ab of red cell invasion by P. vivax merozoites.
For the P. vivax invasion-inhibition experiments, we
exposed schizont-enriched infected blood to the rabbit and
human afﬁnity-puriﬁed anti-PvDBPII Ab on two separate
occasions and counted infected cells. The results presented in
Figure 4 show a reduction of newly invaded red blood cells of
up to 64% (1:100) by the rabbit anti-PvDBPII serum relative
to pre-bleed serum (Student’s t-test, p ¼ 0.070). When the
afﬁnity-puriﬁed human anti-PvDBPII Ab preparation was
added to these short-term in vitro cultures, we observed a
reduction in new P. vivax invasion events by 47% (100 lg/ml)
and 54% (150 lg/ml) when compared to cultures exposed to
nonspeciﬁc human IgG obtained from individuals from non-
endemic areas (Student’s t-test, p , 0.001 and p ¼ 0.042,
respectively). In both of the experiments, rabbit and human
anti-PvDBPII Ab demonstrated a dose-dependent inhibition
of P. vivax merozoite invasion of human red blood cells. The
antibody level inhibiting P. vivax invasion events for the
rabbit anti-PvDBPII serum was between the 1:10 and 1:100
dilutions, and for the human anti-PvDBPII Ab the level was
between 100 and 150 lg/ml.
Discussion
This study demonstrates that anti-PvDBPII Ab obtained
from humans exposed to P. vivax, or artiﬁcially induced in
rabbits, can partially inhibit P. vivax merozoite invasion in
short-term cultures. Our results establish region II of PvDBP
as a prominent ligand engaging the Duffy antigen on human
red blood cells, making it a potential vaccine candidate
against P. vivax. These studies also demonstrate, for what we
believe to be the ﬁrst time, the utility of short-term P. vivax
cultures derived from human isolates for measuring the
invasion-inhibitory potential of antibodies directed against a
speciﬁc merozoite antigen. This approach can be used to test
additional antibodies targeting other P. vivax merozoite
invasion ligands to evaluate potential alternative antigens as
vaccine candidates similar to studies performed more
routinely for P. falciparum [42,43].
In addition to these results, the same anti-PvDBPII Ab were
used in three different binding-inhibition experiments.
Comparing results obtained using these strategies provided
the opportunity to examine potentially complex PvDBP–
Duffy antigen interactions through cell-free and cell-based
assay systems allowing for the possibility that these parasite
and host proteins are likely to take on a range of
conformations in vitro and in vivo. In combination with the
P. vivax invasion-inhibition assay, it is possible to evaluate
consistency between binding assays and interference with P.
vivax infection of human erythrocytes. Overall, the approach
we have taken demonstrates that these in vitro strategies may
identify meaningful correlates of naturally induced immunity
to P. vivax.
From the binding-inhibition assays, which allow PvDBP or
the Duffy antigen to assume multiple conformations, we
observed that PvDBP–Duffy binding occurred as expected in
Figure 2. Inhibition of rPvDBPII Binding to Human Red Blood Cells by
Antibodies
Rabbit (A) and human (B) anti-PvDBPII Ab were tested to observe
inhibition of the interaction of the rPvDBPII protein and Duffy-positive
human erythrocytes. In erythrocyte-binding assays, the bars indicate the
mean binding percentage of four separate experiments (6 standard
deviation) relative to pre-bleed rabbit serum or nonspecific human IgG
(150 lg/ml). In parallel experiments run with Duffy-negative cells,
binding was always ,5% (unpublished data). Fy6 antibodies (50 lg/ml;
recognize N-terminal region of the Duffy receptor) were used to show
relative inhibition compared to the affinity-purified human anti-PvDBPII
Ab.
doi:10.1371/journal.pmed.0040337.g002
Figure 3. Rabbit Anti-PvDBPII Ab Staining of P. vivax Merozoites in
Infected Human Erythrocytes
Rabbit anti-PvDBPII serum binding to fixed P. vivax merozoite,
trophozoite, and schizont (uninfected cells not shown) was confirmed
by immunofluorescence microscopy. Parasites were enriched by Percoll
gradient centrifugation from a Thai patient infected with P. vivax. In the
left panel, PvDBPII is stained green by a 1:10 dilution of rabbit anti-
PvDBPII serum, followed by FITC-conjugated goat anti-rabbit antibody.
In the middle panel, DNA is stained blue by Hoechst. The right panel
shows the overlay of the left and middle micrographs. Additionally, the
antibody concentrated anterior to the nucleus towards the apical end of
the merozoite where PvDBPII is known to be expressed in the
micronemes [18].
doi:10.1371/journal.pmed.0040337.g003
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Inhibition of P. vivax by Anti-PvDBP Abthe absence of anti-PvDBPII–speciﬁc antibody. This inter-
action was inhibited by addition of the anti-PvDBPII–speciﬁc
antibodies in a dose-dependent fashion in all three of the
binding-inhibition assays. Importantly, this was true even for
antibodies afﬁnity puriﬁed from people exposed to natural
infections. Binding inhibition of approximately 50% was
observed to occur at dilutions of the rabbit anti-PvDBPII
serum between 1:1,000 and 1:3,200. Comparisons between the
nDARC-Ig ELISA and erythrocyte-binding assay were similar,
and inhibition of rosette formation in the COS7 cell assay
system occurred at a lower antibody concentration. Using the
human PvDBPII-speciﬁc antibody, binding inhibition was
observed between 3 and 75 lg/ml. These inhibitory antibody
concentrations are consistent with those observed in studies
investigating P. falciparum MSP119 (merozoitesurfaceprotein-1
19) binding [44].
Of further technical interest, it is important to note that
prior to afﬁnity puriﬁcation of anti-PvDBPII Ab, the pooled
human sera showed a 2-fold higher ELISA reactivity to
PvMSP119 when compared with PvDBPII. This potentially
resulted from the ubiquitous expression of PvMSP119 on the
parasite surface and from high levels of P. vivax protein found
in the blood of P. vivax–infected patients. However, after
afﬁnity puriﬁcation of anti-PvDBPII Ab from the pooled
plasma, reactivity speciﬁc for PvDBPII was 4-fold higher than
that of PvMSP119 by ELISA (see Figure S2). We cannot
completely exclude the possibility that high-avidity anti-
bodies directed against PvMSP119, or against other P. vivax
merozoite surface proteins, were in the enriched anti-
PvDBPII Ab preparation and contributed to inhibition of P.
vivax invasion. One laboratory-adapted strain of P. falciparum
tested by Hodder et al. demonstrated that 20 lg/ml of anti-
AMA1 antibody, isolated from pooled human sera under
procedures similar to those used here, was sufﬁcient to
reduce parasite invasion of erythrocytes [45]. However, the
majority of strains tested by Hodder, as well as those
investigated in other previous studies of enriched P.
falciparum anti-AMA1or anti-MSP119 antibodies, required
 100 lg/ml to show signiﬁcant inhibition of P. falciparum
invasion of human erythrocytes [44,45].
Further comparison of these in vitro binding-inhibition
assays illustrates the operational advantages of the nDARC-Ig
ELISA and erythrocyte-binding assay systems; these systems
may promote more efﬁcient identiﬁcation of molecular
strategies to block, or to induce the acquisition of relevant
antibody response against P. vivax infection of human red
Table 1. Invasion of Human Red Blood Cells by P. vivax In Vitro
Experiment Time after Addition
of Red Blood Cells (h)
Late Trophozoites/
Schizonts (%)
Rings/Early
Trophozoites (%)
Total
Parasitemia (%)
1 0 56% 22% 0.045
24 14% 68% 0.103
2 0 60% 40% 0.050
24 34% 47% 0.105
doi:10.1371/journal.pmed.0040337.t001
Figure 4. Inhibition of P. vivax Invasion of Human Red Blood Cells by Anti-PvDBPII Ab
Tests were performed to examine the influence of rabbit (A) and human (B) anti-PvDBPII Ab on P. vivax invasion on a patient sample cultured in PvCM
plus 20% AB serum (Experiment 1) or a sample from a second patient cultured in PvCM plus 25% AB serum (Experiment 2). Control cultures (white bars)
contained media without antibodies and were the same for both experiments. The concentration of antibodies (pre-bleed rabbit serum or nonspecific
human IgG) in the positive control cultures (white bars) was equal to the highest concentration of test serum. Various concentrations of the test
antibody (black bars) were added to late-stage P. vivax cultures and grown for 24 h (in duplicate), and the number of newly invaded cells was observed
by light microscopy based on examination of 200 high-powered fields of Giemsa-stained thin smears or approximately 20,000 erythrocytes. Bars
indicate mean 6 standard deviation of the number of invasion events. p-Values (two-sided t-test) are shown for differences of p , 0.1 between test
samples and their respective control antibody.
doi:10.1371/journal.pmed.0040337.g004
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Inhibition of P. vivax by Anti-PvDBP Abblood cells. Although the exact structure of the nDARC-Ig
molecule is not known, its does bind with high afﬁnity to the
rPvDBPII protein, to the mAb Fy6, which recognizes a linear
epitope in the N-terminal region of the native Duffy antigen,
and to the expected array of chemokines known to interact
with the Duffy antigen [34]. The advantages of the nDARC-Ig
assay include the following: it can be performed using all
recombinant reagents, it is rapidly performed and is easily
standardized, and it uses less than 10 ll of antiserum. The
erythrocyte-binding assay evaluates the interaction between
properly refolded rPvDBPII and the native Duffy antigen
receptor in human red blood cells. The protein–protein
interactions in this assay may therefore better mimic the
parasite–host system, and antibody inhibition may show close
comparability to vaccine-induced immune response. Analysis
of binding inhibition performed by ﬂow cytometry is
quantitative, rapid, and utilizes, at most, 20 ll of antiserum.
A limitation of this assay includes the possibility that
individual serum samples may contain antibodies that are
cross-reactive to erythrocytes provided by different donors
for the assay, resulting in erythrocyte agglutination. Relative
antigen–red cell binding could also vary between assay
donors depending on a range of factors inﬂuencing red
blood cell structure and function. An advantage of the COS7
cell assay is that it avoids expression and puriﬁcation of
recombinant antigen.
Although the rabbit and human anti-PvDBPII Ab demon-
strated between 75 and 100% inhibition of binding in the
three in vitro assay systems described above, similar concen-
trations of antibodies inhibited merozoite invasion by no
more than 50–60%. This difference was not surprising since
the antibodies were pre-incubated with rPvDBPII or COS7
cells expressing PvDBPII in the binding-inhibition assays. By
contrast, the merozoite only expresses PvDBP on the surface
of its apical end just before rupturing the erythrocyte [18].
Therefore, the antigen may not be readily available for
binding to the anti-PvDBPII Ab and higher concentrations
may be required to inhibit parasite invasion. This observation
raises a number of considerations that may inﬂuence immune
recognition and response against PvDBPII. For example, the
same limited exposure of the host immune system to PvDBP
may contribute to the failure by some residents of P. vivax–
endemic areas to develop humoral immunity to PvDBPII [33].
As implied by our previous ﬁndings, the highly polymorphic
nature of PvDBP may also confound development of anti-
bodies capable of inhibiting merozoite invasion of red blood
cells [41]. In this study, we prepared rabbit and human anti-
PvDBPII Ab using Sal 1 rPvDBPII. Since the parasite invasion
experiments were performed with wild strains of P. vivax,
there may be sufﬁcient differences in antibody recognition of
critical binding epitopes leading to reduced efﬁcacy of
invasion inhibition. Ultimately, we can examine this more
closely by comparing antibodies raised against variant PvDBP
alleles.
The low number of parasites available from donor blood
samples contributed to limitations in the number of
conditions that could be evaluated in the in vitro invasion-
inhibition assays. At the present time, donor parasitemia and
the P. vivax preference to invade reticulocytes [46–49]
introduce signiﬁcant limitations to the types of studies that
can be performed. The lengthy transport time of the blood
sample from the clinic to the research laboratories and the
procedures used to remove white blood cells from the
samples resulted in a further reduction in parasitemia.
Recent developments in P. vivax culturing techniques may
reduce the attrition of parasitized cells observed in culture
preparation. Additionally, by supplementing P. vivax cultures
with enriched reticulocyte preparations [28], it may be
possible to improve observation of P. vivax erythrocyte-
invasion events in vitro. Finally, by adapting ﬂow-cytometric
methods used to measure P. falciparum growth and develop-
ment for use with P. vivax, it may be possible to improve
sensitivity of the parasite invasion assays for samples with low
parasitemias [50].
In conclusion, our study provides evidence that antibodies
against PvDBPII inhibit binding to the Duffy receptor and
interfere with P. vivax invasion of human red blood cells. As
our recent study reported that reduced erythrocyte Duffy
expression by Duffy-negative heterozygotes lowers suscepti-
bility to P. vivax blood-stage infection [11,12], our combined
results suggest that there may be an important threshold of
PvDBP–Duffy interaction necessary for parasite invasion of
the human red blood cell. This emphasizes that PvDBP is a
critical parasite invasion ligand to target in P. vivax vaccine
development efforts. Therefore, as the binding-inhibition
assays employed here allow quantitative assessments of the
molecular partners involved in P. vivax human red cell
invasion, it becomes possible to perform highly relevant
assays in high-throughput format to evaluate functional
correlates of immunity against P. vivax blood-stage infection
and disease in population-based studies.
Supporting Information
Figure S1. Evaluation of rPvDBPII Protein Expression and Refolding
(A) Coomassie-stained SDS-PAGE gel, showing M, protein size
markers, rPvDBPII, refolded protein, and rPvDBPIIþDTT, denatured
protein after treatment with 10 mM dithiothreitol.
(B) Results of an erythrocyte-binding assay, with refolded rPvDBPII
after preadsorption with Duffy-positive and Duffy-negative eryth-
rocytes. The binding assay was performed by incubating erythrocytes
with refolded protein, and the reaction mixture was then layered over
dibutylpthalate (Sigma) and centrifuged to collect erythrocytes.
Bound protein was eluted from erythrocytes with 300 mM NaCl;
unbound protein demonstrates that there was the same amount of
protein added to each well. The rPvDBPII protein was detected by
Western blotting with anti-HIS monoclonal antibodies conjugated to
horseradish peroxidase. Note that the refolded protein forms two
bands that might represent slight variations in the way the protein
refolds. This same pattern has been observed previously by Singh et
al. [25].
Found at doi:10.1371/journal.pmed.0040337.sg001 (30 KB PDF).
Figure S2. ELISA to Determine Titer of Antibodies
Rabbit antiserum was raised against the rPvDBPII Sal 1 variant. (A)
ELISA titers of the rabbit antiserum to rPvDBPII Sal 1 and C variants.
(B) Titers of afﬁnity-puriﬁed human anti-PvDBPII Ab when attached
to Sal 1 and C variants of rPvDBPII and to recombinant PvMSP119,a
highly immunogenic antigen widely recognized by human anti-P.
vivax antibodies [51].
Found at doi:10.1371/journal.pmed.0040337.sg002 (22 KB PDF).
Figure S3. COS Cell Binding Assay
The COS cell binding assay reports the average of three independent
experiments, each performed in triplicate on the rabbit anti-PvDBPII
serum. The inoculated rabbit serum blocked COS7 cells expressing
PvDBPII from forming rosettes in a dose-dependent fashion, leading
to an indication that the PvDBPII was correctly folded and that
antibodies directed against this protein were effective in interrupting
the PvDBPII–Duffy interaction.
Found at doi:10.1371/journal.pmed.0040337.sg003 (14 KB PDF).
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Editors’ Summary
Background. Malaria is a parasitic infection transmitted to people
through the bite of an infected mosquito. Four different parasites cause
malaria—the commonest and most widely distributed of these is
Plasmodium vivax. Infections with P. vivax are rarely fatal, but they
cause debilitating chills and fevers that recur every other day if
untreated. Like other malaria parasites, P. vivax has a complex life cycle.
Infected mosquitoes inject a form of the parasite known as sporozoites
into people. The sporozoites replicate inside liver cells without causing
any symptoms. Then, 8–9 d later, merozoites (another form of the
parasite) are released from the liver cells and invade young red blood
cells. Here, they replicate rapidly before bursting out and infecting more
red blood cells. The characteristic symptoms of malaria are caused by
this cyclical increase in the parasite burden. P. vivax infections are usually
treated with chloroquine, but patients must also take a second drug
called primaquine. This drug kills hypnozoites, a form of the parasite that
hibernates in the liver and that can cause a relapse many months after
the initial bout of malaria.
Why Was This Study Done? P. vivax is becoming resistant to
chloroquine and, although other antimalarial drugs still kill it, a vaccine
that would limit the severity of P. vivax infections by blocking its ability
to invade red blood cells is urgently needed. The invasion of red blood
cells by P. vivax depends on an interaction between the Duffy antigen (a
protein on the surface of human red blood cells) and the Duffy binding
protein (PvDBP), which is expressed by merozoites. People who lack the
Duffy antigen are resistant to blood-stage infections of P. vivax. Similarly,
people who express half the normal amount of Duffy antigen on their
red blood cells have reduced susceptibility to these infections. In this
study, the researchers investigated whether antibodies (proteins made
by the immune system that recognize foreign proteins) directed against
PvDBP inhibit the invasion of human red blood cells by P. vivax.
What Did the Researchers Do and Find? The researchers injected a
fragment of PvDBP called PvDBPII into rabbits and purified the part of
the blood that contains antibodies from the animals. They also isolated
antibodies to PvDBPII from the blood of several Papua New Guineans
who had been exposed to P. vivax. Both types of antibodies bound to
PvDBPII in test tubes and to PvDBP expressed on P. vivax merozoites.
Then, the researchers showed that both types of antibody inhibited the
binding of PvDBPII to Duffy antigen when the antigen was in solution
and when it was present on human red blood cells. Finally, to test the
ability of the antibodies to inhibit red blood cell invasion by P. vivax, the
researchers established short-term cultures of the parasite from blood
taken from infected adults living in Thailand. Addition of the rabbit or
human antibodies to these cultures inhibited parasite invasion of red
blood cells by more than 50%.
What Do These Findings Mean? These findings show, for what is
believed to be the first time, that antibodies recognizing a fragment of
PvDBP can partly inhibit the invasion of red blood cells by P. vivax
merozoites. The results with the human antibodies are particularly
important as they strongly suggest that a PvDBP-based vaccine might
provide protection against blood-stage P. vivax infections. Whether the
level of inhibition of invasion seen in this study will be sufficient to
reduce the clinical severity of these infections will only become clear,
however, when a vaccine is tested in people. The findings also indicate
that short-term P. vivax cultures can be used to test whether antibodies
that recognize other merozoite proteins also inhibit invasion. Unlike P.
falciparum (the other major malarial parasite), P. vivax cannot be grown
continuously in the laboratory. These short-term cultures will at last
provide vaccine developers with a way to evaluate antigens as
candidates for inclusion in P. vivax vaccines.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040337.
  MedlinePlus encyclopedia page on malaria (in English and Spanish)
  Information from the US Centers for Disease Control and Prevention
on malaria (in English and Spanish)
  Vivaxmalaria, information for the malaria research community on
topics related to Plasmodium vivax
  Information from the Malaria Vaccine Initiative about malaria and
malaria vaccines, including a fact sheet on Plasmodium vivax malaria
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